483
GlaxoSmithKline, LLC.FDA 483 - GlaxoSmithKline, LLC. - September 25, 2024
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
Record Details
An FDA inspection of GlaxoSmithKline, LLC in Conshohocken, PA, revealed significant deficiencies in their drug substance manufacturing operations. The firm failed to ensure adequate controls against contamination, properly validate manufacturing processes, and conduct thorough investigations into discrepancies. Furthermore, issues with data integrity and overall Quality Unit oversight were identified, indicating a broad lack of GMP compliance.
Open in Dashboard
ID · 2e61f4bb-ceab-409d-9c7e-ad3739096580